N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine

Soo Huey Yap, Brian D. Herman, Jessica Radzio, Nicolas Sluis-Cremer, Gilda Tachedjian

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The efficacy of regimens that include both zidovudine and nevirapine can be explained by the synergistic interactions between these drugs. N348I in HIV-1 reverse transcriptase confers decreased susceptibility to zidovudine and nevirapine. Here, we demonstrate that N348I reverses the synergistic inhibition of HIV-1 by zidovudine and nevirapine. Also, the efficiency of zidovudine-monophosphate excision in the presence of nevirapine is greater for N348I HIV-1 reverse transcriptase compared with the wild-type enzyme. These data help explain the frequent selection of N348I in regimens that contain zidovudine and nevirapine, and suggest that the selection of N348I should be monitored in resource-limited settings where these drugs are routinely used.

Original languageEnglish (US)
Pages (from-to)153-157
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume61
Issue number2
DOIs
StatePublished - Oct 1 2012

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine'. Together they form a unique fingerprint.

Cite this